Ipsen: presents phase III NAPOLI 3 trial

(CercleFinance.com) - At ASCO GI Ipsen presented the NAPOLI 3 phase III trial of the Onivyde regimen, which showed positive survival results in previously untreated metastatic pancreatic ductal adenocarcinoma.


The investigational Onivyde treatment (irinotecan liposome injection) in the NALIRIFOX treatment regimen demonstrated statistically significant improvements in overall survival and progression-free survival compared to nab-paclitaxel plus gemcitabine with a manageable safety profile.

Ipsen said that these results represent a potential breakthrough in an aggressive and difficult-to-treat cancer.


Copyright (c) 2023 CercleFinance.com. All rights reserved.